Molecular pathology of acute respiratory distress syndrome, mechanical ventilation and abnormal coagulation in severe COVID-19

Antoine Soulé^{1,*}, William Ma^{1,*}, Katelyn Yixiu Liu², Catherine Allard³, Salman Qureshi², Karine

Tremblay^{4, †}, Amin Emad^{1, 5, †} and Simon Rousseau^{2, †}

* These authors contributed equally.

¹ Department of Electrical and Computer Engineering, McGill University, Montréal, QC, Canada

² The Meakins-Christie Laboratories at the Research Institute of the McGill University Heath Centre Research Institute, & Department of Medicine, Faculty of Medicine, McGill University, Montréal, QC, Canada

³ Statistical department, Centre de recherche du Centre hospitalier universitaire de Sherbrooke (CRCHUS), Sherbrooke, Canada.

⁴ Pharmacology-physiology Department, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Saguenay, QC, Canada; Centre intégré universitaire de santé et de services sociaux du Saguenay-Lac-Saint-Jean, Saguenay, QC, Canada; CRCHUS, Sherbrooke, Canada.

⁵ Mila, Quebec Al Institute, Montréal, QC, Canada

+ Co-corresponding Authors:

Simon Rousseau, RI-MUHC, E M3.2244, 1001 Décarie, Montréal H4A 3J1, Canada, Email: simon.rousseau@mcgill.ca

Amin Emad, 755 McConnell Engineering Building, 3480 University Street, Montreal H3A 0E9, Canada Email: amin.emad@mcgill.ca

Karine Tremblay, Pavillon des Augustines, local AUG-5-01A, 225 St-Vallier street, Chicoutimi G7H 7P2, Canada Email: karine.tremblay@usherbrooke.ca

1 Abstract

2 Systemic inflammation in critically ill patients can lead to serious consequences such as acute 3 respiratory distress syndrome (ARDS), a condition characterized by the presence of lung 4 inflammation, edema, and impaired gas exchange, associated with poor survival. Understanding 5 molecular pathobiology is essential to improve critical care of these patients. To this end, we use 6 multimodal profiles of SARS-CoV-2 infected hospitalized participants to the Biobanque 7 Québécoise de la COVID-19 (BQC-19) to characterize endophenotypes associated with different 8 degrees of disease severity. Proteomic, metabolomic, and genomic characterization supported a 9 role for neutrophil-associated procoagulant activity in severe COVID-19 ARDS that is inversely 10 correlated with sphinghosine-1 phosphate plasma levels. Fibroblast Growth Factor Receptor 11 (FGFR) and SH2-containing transforming protein 4 (SHC4) signaling were identified as molecular 12 features associated with endophenotype 6 (EP6). Mechanical ventilation in EP6 was associated 13 with alterations in lipoprotein metabolism. These findings help define the molecular mechanisms 14 related to specific severe outcomes, that can be used to identify early unfavorable clinical 15 trajectories and treatable traits to improve the survival of critically ill patients.

17 Introduction

18 Acute respiratory distress syndrome (ARDS), a condition characterized by the presence of lung 19 inflammation, edema, and impaired gas exchange, is observed in severe coronavirus disease 20 2019 (COVID-19) and associated with poor survival. Mechanical ventilation is an important critical 21 care management strategy for severe COVID-19 (1). However, during the first waves of the 22 pandemic, almost half of patients undergoing invasive mechanical ventilation died based on case 23 fatality rate reports (2). Defining the molecular mechanisms related to specific severe outcomes, 24 such as ARDS or acute respiratory failure that require invasive mechanical ventilation, is 25 important to identify treatable traits and improve the survival of critically ill patients.

26

Endophenotypes are subgroups which are inapparent to traditional methods but share a common set of factors that dictate their response in a manner that is distinct from other subgroups (3). Endophenotypes have been described in airway diseases such as asthma (4), COPD, (5) and chronic rhinosinusitis (6). Recent studies have identified endophenotypes associated with COVID-19 severity using different large data sets, such as bulk transcriptomic from blood (7), bulk transcriptomic from neutrophil-enriched fractions (8), or proteomic in our accompanying manuscript (9).

34

In this manuscript, we report multimodal characterization of one of the six endophenotypes (EPs)
 identified in our accompanying manuscript (9), which we found to be associated with the worst
 clinical trajectory during hospitalization following SARS-CoV-2 infection (including ARDS). This

analysis reveals known and novel molecular effectors of immuno-thrombosis, ARDS and
 mechanical ventilation associated with COVID-19.

40

41 Results

42 Serprocidins are enriched in an endophenotype associated with COVID-19 severity and ARDS

43 To gain insight into the molecular mechanisms underlying the severity in COVID-19, we 44 investigated the aptamers enriched within an endophenotype (EP6) (Figure 1 and Table S1) that 45 we previously discovered using the circulating proteome of SARS-CoV-2 infected and hospitalized participants to BQC19 (n = 731) and found to be associated with severe outcome and ARDS (9). 46 47 These aptamers correspond to measurements obtained using a multiplex SOMAmer affinity 48 array. We used two-sided Mann–Whitney U (MWU) tests and the p-values were corrected for the number of aptamers and EPs using Benjamini–Hochberg (BH) false discovery rate (FDR). 49 50 Consistent with the elevated neutrophil numbers in EP6, the most enriched aptamer was 51 Cathepsin G (FDR = 4.10E-58), a serine protease localized in neutrophil azurophil granules. 52 Notably, two other serprocidins, neutrophil elastase and proteinase-3, were also significantly 53 enriched in EP6 (FDR = 1.04E-10 and FDR = 8.27E-7, respectively, Figure 1 and Table S1). 54 Moreover, another NETosis-associated protein, Olfactomedin 4 (OLFM4) (10), was greatly 55 enriched in EP6 (top 5%; FDR = 2.61E-46, Figure 1 and Table S1). This suggests an important role 56 for neutrophil degranulation and/or NETosis in severe COVID-19.

57

Pathway enrichment analysis identified FGFR-signaling in severe COVID-19 acute respiratory
 distress syndrome

60 To capture a more comprehensive landscape of the signaling networks active in EP6, we 61 performed pathway enrichment analysis using the Knowledge Engine for Genomics (KnowEnG) 62 (11). Since aptamers were used to identify the EPs, it is expected that many of them would have 63 significant associations with the EPs. As a result, we selected a very strict threshold of FDR < 1E-64 20 (two-sided MWU test, BH FDR) to identify top aptamers associated with EP6 (9). We then used 65 the gene set characterization pipeline of KnowEnG with Reactome pathway collection (12). This analysis showed that EP6 is characterized by pathways associated with interleukins and cytokine 66 67 signaling in the immune system. In addition, fibroblast growth factor receptor (FGFR) signaling was identified in EP6, suggesting this pathway as a potential driver of severe pathology (Table 1 68 69 and S1).

70

71 EP6 metabolomic signature was associated with pro-coagulant activities and liver dysfunction 72 To further characterize the pathobiology of severe COVID-19 disease, metabolomic profiling of 73 plasma samples was performed in parallel to the aptamer analysis. The results yielded data on 74 1,435 metabolites, of which 576 were found significantly altered in EP6 (two-sided MWU FDR < 75 0.01) (Table S2). Characterization of the plasma samples supported the distinction among the 76 different EPs at the levels of metabolomic sub-pathways and individual metabolites (Figure 2 and 77 Table S2). The two top sub-pathways (FDR < 0.01) "Methionine, Cysteine, SAM and Taurine 78 Metabolism" and "phosphatidinylethanolamine (PE)", are known to interact (13, 14) and are associated with pro-coagulant activities. Phospholipids-containing microparticles from platelet 79 80 activation contribute to Tissue Factor activation and pro-thrombinase activity (15), linking PE to 81 coagulation and D-dimers level, which are elevated in EP6 (9). PE methylation acts as a major

82 consumer of S-Adenosylmethionine (SAM) leading to the synthesis of S-Adenosylhomocysteine 83 (SAH) and cystathionine (14), upstream of 2-hydroxybutyrate and 2-aminobutyrate in a model of 84 hepatoxicity (16). SAH, cystathionine, 2-hydroxybutyrate and 2-aminobutyrate are all 85 significantly enriched in EP6 (Figure 2B and 3A). To identify relationships that may shed light on 86 factors influencing clinical laboratory results that define EP6, we also performed Spearman's rank 87 correlation analyses between 21 blood variables and metabolites (Table S3). SAH is positively 88 correlated with creatinine, while cystathionine is positively correlated with creatinine and 89 negatively correlated with albumin (Figures 4, S1-S2), congruent with the data from the model of 90 hepatoxicity (16), linking abnormal coagulation and liver damage in severe COVID-19. We also 91 observed kynurenine to be enriched in EP6 but depleted in EP1 (Figures 3 and 5). Kynurenine 92 levels were also found to be positively correlated with D-Dimers levels (Figure 4 and S1-S2), 93 suggesting a role of this metabolite of the tryptophan pathway in abnormal coagulation in severe 94 COVID-19. Interestingly, TNFSF18 (GITR), a T-cell receptor that can activate indoleamine 2,3-95 dioxygenase (IDO) to increase kynurenine synthesis (17) in allergy, is enriched in EP6 and 96 depleted in EP1 (Figures 3 and 5).

97

98 Low levels of sphingosine-1 phosphate are associated with COVID-19 ARDS

99 Strikingly, sphingosine-1 phosphate was enriched in EP1 and depleted in EP6 (Figures 3 and 5), 100 confirming the previously reported negative association of this metabolite with COVID-19 ARDS 101 (18). Accordingly, the aptamer detecting neutral ceramidase, an enzyme converting ceramides 102 into sphingosine, is enriched in EP1 (FDR = 2.65E-10, Table S1). While changes in protein 103 abundance as detected by aptamers may not necessarily reflect changes in enzymatic activity, it

is interesting to note that dihydroceramides and ceramides are depleted in EP1 (Figure 5, Table
S1). Conversely, dihydroceramides and ceramides are significantly enriched in EP6 (Figure 3,
Table S1). Moreover, one of the top aptamers found enriched in EP6 (FDR = 2.10E-56, Figure 1)
is serine palmitoyltransferase 2 (SPTLC2), an enzyme that is responsible for the rate-limiting step
in *de novo* sphingolipid biosynthesis (19, 20).

109

110 Mechanical ventilation in EP6 is associated with lipoprotein metabolism

111 As noted in the introduction, mechanical ventilation in COVID-19 is associated with a high 112 mortality rate. Within EP6, 55 out of the 118 individuals received mechanical ventilation. Within 113 all EP6 members that share the overall similar aptamer signature, we identified a subset of 114 aptamers and metabolites that were significantly different between those with or without 115 mechanical ventilation (Figure 6A and Table S4). The second most enriched aptamer (Table 2 and 116 S4), angiopoietin-like 3 (ANGPTL3), corresponds to a liver-secreted regulator of lipoprotein 117 metabolism (21), which may reflect alterations observed in fatty acid metabolites (Table S4). 118 There were no significant differences between the two groups in terms of sex, age, or body mass 119 index (BMI) (Figure 6B-6C and Table S4). Finally, we investigated whether molecular information 120 (proteomic and/or metabolomic) was associated with mechanical ventilation duration. We 121 identified alpha-L-iduronidase (IDUA) to be inversely correlated with duration of ventilation in 122 the patients with mechanical ventilation in EP6 (Spearman's rank correlation = -0.60, FDR = 2.57E-123 2, Figure 6D and Table S4). Overall, these results point to an association between altered 124 lipoprotein metabolism and mechanical ventilation in EP6.

125

126 SHC4 genotype and protein expression levels are associated with higher odds of belonging to

127 EP6

To obtain independent support for the involvement of specific proteins identified using 128 129 aptamers, we leveraged genome-wide association study (GWAS) genotyping data corresponding 130 to these patients. We identified 25 single nucleotide variations (SNVs) distributed in 13 annotated 131 genes that were below a p-value threshold of 1E-4 and distinguished EP6 from the rest (Table 3). 132 We then investigated each of the SNVs to which we could assign a gene and an aptamer, to assess 133 whether their protein product in circulation was differentially regulated by the genotype (Table 134 4). We discovered two genes, SHC4 (encoding SHC adaptor protein 4) and CACNA2D3 (encoding 135 calcium voltage-gated channel auxiliary subunit alpha2 delta3) for which there was a significant 136 association between genotype and protein expression levels (p-values < 0.05). While CACNA2D3 137 may have mild impact on EP6 membership (odds ratio = 0.61, Table 4), SHC4 was one of the top-138 enriched aptamers (position 32 out of 4,985, Figure 1) for inclusion in EP6, with an odds ratio of 139 11.98 for the protein product and 2.00 for the alternate allele, respectively. Finally, to gain further 140 insight into the potential role of SHC4 in COVID-19 disease severity, we investigated the 141 metabolites associated with SHC4 in EP6. The only significantly correlated metabolite was 6-142 oxopiperidine-2-carboxylate (Spearman's rank correlation = 0.40, FDR = 0.012, Figures 4, S1-S2), 143 where the p-values were corrected for the number of metabolites using BH FDR. Therefore, the 144 GWAS analysis revealed that the signaling adaptor protein SHC4 may play an important 145 mechanistic role in contributing to severe disease pathology.

146

147 Discussion

148 In this study, we leveraged the molecular features associated with endophenotypes discovered 149 using unsupervised hierarchical clustering of circulating proteome of SARS-CoV-2 positive 150 hospitalized participants to BQC19 to improve our understanding of pathobiology. This approach 151 enabled the identification of the following molecular features: 1) the level of Sphingosine-1 152 phosphate is highest in EP1 and lowest in EP6, reflecting an inverse association with time to 153 admission to ICU and/or death; 2) interleukins and FGFR signaling are molecular pathways 154 associated with severe COVID-19; 3) genetic and environmental determinants of SHC4 expression 155 are associated with inclusion in EP6; 4) the combined proteomic and metabolomic signature of 156 EP6 supports a pathologic role for neutrophil-associated procoagulant activity in COVID-19 ARDS; 157 and 5) mechanical ventilation in EP6 is associated with altered lipoprotein metabolism.

158

159 COVID-19 ARDS molecular pathology: a counterbalance between ceramides and sphingosine is
160 associated with critical illness.

161 The datasets used in this study carry rich molecular information on mechanisms of disease for 162 COVID-19. EP6 is characterized by its enrichment in ARDS (50% vs 9% in EP1), acute kidney injury 163 (50%) and liver dysfunction (22%) (9). Low levels of Sphingosine 1-phosphate (S1P) are associated 164 with ARDS and have been shown to be associated with greater ICU admission and decreased 165 survival in COVID-19 (18), and is supported by this study where S1P levels were found depleted 166 in EP6 but enriched in EP1 (the endophenotype with the best prognostic). The study also supports 167 a shunting away from sphingosine towards more pro-inflammatory ceramides that are associated 168 with metabolic disorders (22), suggesting a counterbalance between ceramides and sphingosine,

- where the former is associated with poorer outcomes during critical illness, whereas higher levelsof the latter is associated with more favorable outcomes in ARDS.
- 171

172 Molecular mechanisms of mechanical ventilation in EP6: a potential role for ANGPTL3

173 ANGPTL3 is a liver-secreted enzyme that can inhibit lipoprotein and endothelial lipase (23). Loss-174 of-function of ANGPTL3 is associated with hypolipidemia (24). Therefore, increased circulating 175 levels of ANGPTL3 would be expected to raise plasma levels of triglycerides and phospholipids 176 which is consistent with the observed metabolomic profiles (Table S4). Whether these alterations are sufficient to increase the likelihood of mechanical ventilation remains speculative. 177 178 Nevertheless, it is interesting to note that administration of medium- and long-chain triglycerides 179 can aggravate gas exchange abnormalities in ARDS (25) and may warrant the preclinical 180 investigation of ANGTPL3 antagonists like evinacumab or other functionally similar therapeutic 181 agents (26) in ameliorating outcomes in ARDS. As for the duration of mechanical ventilation, we 182 discovered an inverse correlation with IDUA, a lysosomal enzyme required for the degradation 183 of heparan sulfate and dermatan sulfate (27). Our current data cannot distinguish between the 184 presence of this enzyme as a biomarker or as an active mediator that influences the course of 185 COVID-19-associated acute respiratory failure.

186

187 Multimodal profiling of EP6 supports a role for neutrophil-derived procoagulant activity-mediated
188 organ damage in COVID-19.

189 COVID-19 ARDS has been found to be more frequently associated with thrombotic complications
190 than non-COVID-19 ARDS (28, 29). In addition, histopathologic evidence of pulmonary

medRxiv preprint doi: https://doi.org/10.1101/2023.03.09.23286797; this version posted March 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

191 microthrombi is frequently observed in autopsies of individuals deceased with COVID-19 (30). 192 Early reports suggested a role for neutrophil-mediated release of NETs contributing to 193 endothelial dysfunction as a mechanism of microthrombosis in COVID-19 ARDS (31-42). The 194 neutrophil-derived serprocidins cathepsin G, neutrophil elastase, and proteinase-3, are 195 significantly enriched in EP6. In addition to their roles in bacterial killing, serprocidins couple 196 innate immunity to coagulation, where they promote coagulation by enhancing tissue factor and 197 factor XII-dependent coagulation (43). Serprocidins are also important regulators of NETosis (44). 198 In pediatric sepsis, another NETosis-associated protein olfactomedin 4 (OLFM4) (10), enriched in 199 EP6, is associated with increased odds of having greater organ failure and death (45). The 200 procoagulant environment associated with COVID-19-associated organ damage is further 201 supported by the alteration in metabolic profiles in EP6. Phosphatidinylethanolamines (PE) 202 become exposed at the surface of cell membranes upon exposure to stress, inflammation, and 203 cell death (46, 47). In a Syrian hamster model, infection with SARS-CoV-2 markedly increased 204 circulating PE expression in the animals that were fed a high salt, high fat diet, demonstrating the 205 interaction between infection and metabolic disorder (48). Furthermore, the membranes of 206 azurophilic granules, which contain serprocidins, are enriched in PE (49). Accordingly, EP6 is 207 associated with decreased platelet counts, increased D-Dimers, international normalized ratio 208 (INR) and activated partial thromboplastin time (aPTT) (9), hallmarks of abnormally activated 209 coagulation pathways that are associated with serious and often lethal complication of sepsis 210 (50). Accordingly, we report an association between kynurenine and D-dimer, pointing to an 211 involvement of tryptophan metabolism in abnormal coagulation. Interestingly, TNFSF18, a T-cell 212 receptor that promotes leukocyte adhesion to endothelial cells (51), is enriched in EP6. A SNV

213 found in the proximity of TNFSF18 was found associated with severity of COVID19 in the western 214 Indian population (52). Unfortunately, this SNV was absent from the array used in BQC19 215 preventing the confirmation of that observation, but it is nevertheless suggestive of a link 216 between TNFSF18, kynurenine, and abnormal coagulation in severe COVID-19. Collectively, these 217 findings point to immuno-thrombosis activity in EP6 in response to SARS-CoV-2 infection that is 218 associated with abnormal coagulation. Recent results from the Antithrombotic Therapy to 219 Ameliorate Complications of COVID-19 (ATTACC) study showed anticoagulation to be efficacious 220 in moderate but not severe COVID-19 disease (53, 54), revealing a need for alternative 221 management approaches in critically ill patients.

222

223 Novel molecular markers of COVID-19 pathology: FGFR and SHC4

224 Two novel molecular factors associated with COVID-19 ARDS that were identified by our study 225 are FGFR and SHC4. Circulating levels of the pro-angiogenic FGF-2 has been associated with 226 COVID-19 severity and creatinine levels in a study of 208 SARS-CoV-2 positive participants (55). 227 It is also noteworthy that the use of nintedanib, an inhibitor of FGFR, vascular endothelial growth 228 factor receptor (VEGFR), and platelet-derived growth factor receptor (PDGF-R) that is approved 229 for use in interstitial lung disease, improved pulmonary inflammation and helped three middle-230 aged obese COVID-19 patients with markedly impaired lung function wean off mechanical 231 ventilation (56). While the adaptor protein SHC4 has not been experimentally demonstrated to 232 modulate FGFR signaling, a 12-gene biomarker signature associated with melanoma contains 233 FGFR2, FGFR3 and SHC4 (57). It is attractive to speculate that SHC4 may act downstream of FGFR 234 or other associated growth factor receptors, favoring heightened procoagulant activity

235 associated with COVID-19 ARDS. In view of the limited knowledge of this understudied member 236 of the SHC family, we looked at the metabolites associated with SHC4 to gain insights into its 237 possible functions. Interestingly, 6-oxopiperidine-2-carboxylate (the only metabolite with a 238 significant correlation with SHC4 in EP6) was found to be negatively associated with glomerular 239 filtration rate in a GWAS study of kidney disease and hypertension in African Americans (58). 240 Acute kidney injury is a frequent complication of acute liver failure (59), and liver dysfunction is 241 associated with abnormal coagulation (60). Thus, the overall molecular information coming from 242 the multi-modal analysis of EP6 points to a triad between liver function, kidney function, and 243 hemostasis that becomes dysfunctional following ARDS-associated inflammation driven by SARS-244 CoV-2 infection. Whether the presence of SHC4 in circulation is a marker of dysfunction of this 245 triad, or an active mediator, remains to be determined. Moreover, the identity of the cells 246 expressing SHC4 leading to its presence in the circulation is not known. Taken together, our 247 identification of FGFR and SHC4 signaling pathways distinguishing EP6 from other 248 endophenotypes provides a rationale for investigation of their potential utility as biomarkers of 249 severe disease activity and/or the use of antagonists of those pathways to treat severe COVID-250 19 disease manifestations.

251

252 Methods:

253 Datasets and preprocessing

We obtained data corresponding to clinical, genomics, metabolomics, and proteomics (circulating proteome) of n = 731 hospitalized and SARS-CoV-2 positive patients (based on qRT-PCR) from the Biobanque Québécoise de la COVID-19 (BQC19; www.quebeccovidbiobank.ca).

The circulating proteome measurements obtained using a multiplex SOMAmer affinity array (SomaLogic, 4,985 aptamers) between April 2020 and April 2021 were preprocessed and used to identify six endophenotypes (EP1-EP6). The details of the cohort, circulating proteome data processing, and identification of endophenotypes are provided in the accompanying manuscript (9).

262

263 In this study, we used the batch-normalized, missing-values-imputed, and log-transformed 264 version of the BQC19 metabolomic data (1,435 metabolites). BQC19 GWAS imputation data were 265 generated by Tomoko Nakanishi at Brent Richards lab, Jewish General Hospital and McGill be 266 University. Detailed codes used for generating the data found can in: 267 https://github.com/richardslab/BQC19 genotype pipeline.

268

269 Analyses of the GWAS dataset

270 For the GWAS analyses, annotation of SNVs were done using the biomaRt package (61) from R 271 (62), and all analyses were done using R version 4.1.3. Quality control steps were derived in 272 majority from a 2017 QC tutorial article (63). At the beginning, we had 867,450 markers and 2,429 273 samples. We imported Plink format data into R using the "read_plink" function from genio R 274 package (64). We removed 103,592 non ACGT bi-allelic markers. We calculated the predicted sex 275 by looking at the rate of homozygote markers on chromosome 23. We removed 3,588 markers 276 with call rates < 98%, 448,932 monomorphic markers and markers with MAF < 0.05, and 28,092 277 markers with Hardy–Weinberg equilibrium < 1E-6 (calculated by the "HWE.exact" function from 278 the genetics package (65) from R. For the EP6 cluster group analyses, we additionally removed

279 1,747 samples that were not in the cluster analysis, 8 samples with a sex discrepancy (based on 280 predicted sex calculated earlier and reported sex), and 3 samples with a heterozygosity rate > 3 standard deviations. We finally removed a pair of samples which had approximately the same 281 282 genome, likely due to an error of manipulation. As we could not know which one was correct, we 283 removed both. We also found 2 pairs of individuals with a pi-hat of ~0.5 (meaning first degree 284 relatives), so we kept the one sample per pair with the higher call rate. All other pairs of 285 individuals had a pi-hat < 0.21 that is judged acceptable considering our population. Pi-hats were 286 calculated with the "snpgdsIBDMoM" function from SNPRelate R package (66). At the end of 287 quality controls, 283,246 markers on 655 samples had been used to perform association analyses.

288

To perform the principal component analyses (PCA), we took a subsample of independent markers (pruning) with a maximum sliding window of 500,000 base pairs and a linkage disequilibrium (LD) threshold of 0.2 using the "snpgdsLDpruning" function from the SNPRelate R package. We ran the PCA with the "snpgdsPCA" function from SNPRelate package from R. The first 2 principal components (PCs) were considered significant.

294

For the GWAS analyses of the 283,246 remaining markers between EP6 cluster compared to all others, we used a logistic regression model, with the dichotomous variable indicating if the participants belong to the EP6 cluster as the outcome variable. We used the additive model for markers as an independent variable, and we adjusted the models with the first two PCs. Odds ratio and p-values were calculated on each model. Quantile–quantile (Q–Q) plots have been performed as quality control of the models; p-values were plotted using "qqplot.pvalues"

301 function from gaston R package (67) (data not shown). We compared the aptamers' normalized 302 level of expression between the three groups of genotypes for each studied gene by performing 303 standard analysis of variance (ANOVA) analyses followed by Tukey post hoc tests (referred to in 304 this study as pQTL analysis). Since aptamers tested are limited compared to SNVs, we fixed 305 significance p-value threshold below 1E-4 to report more SNVs instead of the more common 1E-306 5 suggestive threshold. Finally, to identify if EP6 may be characterized by the aptamers and the 307 SNVs, we performed multiple logistic regression analysis including aptamers expression values, 308 SNV genotypes (additive model), and the two principal components. Odds ratios are reported 309 with 95% confidence intervals.

310

311 Metabolomic pathway characterization of EP6

The 1,435 metabolites measured were organized into 122 sub-pathways in the original dataset (denoted as "SUB_PATHWAYS"). We first identified metabolites whose values were significantly higher or lower in EP6 compared to other EPs (two-sided MWU test, FDR<0.01). Then, we used these metabolites to perform pathway enrichment analysis (one-sided Fisher's exact test) based on 122 pathways. The resulting p-values were then corrected for multiple tests using Benjamini– Hochberg FDR.

318

319 Statistics

Several non-parametric tests, including the MWU test, Fisher's exact test, and Spearman's rank
 correlation, were used in this study. Benjamini–Hochberg FDR was used to adjust the p-values
 for multiple tests.

323

324 Study approval

The study was approved by the Institutional Ethics Review Board of the "Centre intégré universitaire de santé et de services sociaux du Saguenay-Lac-Saint-Jean" (CIUSSS-SLSJ) affiliated to the Université de Sherbrooke [protocol #2021-369, 2021-014 CMDO – COVID19].

328

329 Acknowledgements

330 This work was made possible through open sharing of data and samples from the Biobanque 331 Québécoise de la COVID-19, funded by the Fonds de recherche du Québec - Santé, Génome 332 Québec, the Public Health Agency of Canada and, as of March 2022, the Ministère de la Santé et 333 des Services Sociaux du Québec. We thank all participants to BQC19 for their contribution. This 334 study was supported by the Fonds de recherche du Québec - Santé (FRQS)- Cardiometabolic 335 Health, Diabetes and Obesity Research Network (CMDO)- Initiative. This work was also supported 336 by Natural Sciences and Engineering Research Council of Canada (NSERC) grant RGPIN-2019-337 04460 (AE).

338


339 Conflict of Interests

340 The authors have declared that no conflict of interest exists.


341

342






- 346 **Figure 1:** Distribution of aptamer expressions in EP6 versus other EPs.
- 347 The violin plots show the distribution of aptamer expressions for patients in EP6 (magenta) versus
- 348 EP1-5 (teal). Two-sided Mann–Whitney U (MWU) tests followed by Benjamini–Hochberg method
- 349 for adjusting the p-values were used to calculate false discovery rates.




350

351 **Figure 2:** Metabolite characteristics of endophenotypes (EPs).

A) The heatmap shows the enrichment (one-sided Fisher's exact test) of EPs in different metabolite sub-pathways. See Table S2 for the full list. B) The heatmap shows the overexpression (red) and under-expression (blue) of metabolites in different EPs (two-sided Mann-Whitney U test). Row names show metabolites followed by the sub-pathway to which they belong in parentheses. Only top 15 metabolites (based on false discovery rate for EP6) for which a definite mag






358

359 Figure 3: Distribution of metabolite levels in EP6 versus other EPs.

360 The violin plots show the distribution of metabolite levels for patients in EP6 (magenta) versus

- 361 EP1-5 (teal). Two-sided Mann–Whitney U (MWU) tests followed by Benjamini–Hochberg method
- 362 for adjusting the p-values were used to calculate false discovery rates.



363


Figure 4: Correlation between different variables in EP6.

Each circle in the scatter plots correspond to a patient in EP6. The circles are colored based on
 the density of points surrounding them for clearer visualization. SCC corresponds to Spearman's

367 rank correlation coefficient. A) Scatter plots reflecting the correlation between metabolites (y-

368 axis) and blood variables (x-axis). B) Scatter plot corresponding to correlation of 6-oxopiperidine-

369 2-carboxylate and SHC4.



370

- 371 Figure 5: Distribution of metabolite levels in EP1 versus other EPs.
- 372 The violin plots show the distribution of metabolite levels for patients in EP1 (red) versus EP2-6
- 373 (blue). Two-sided Mann–Whitney U (MWU) tests followed by Benjamini–Hochberg method for
- 374 adjusting the p-values were used to calculate false discovery rates.




Figure 6: Mechanical ventilation in EP6.

A) The violin plots show the distribution of aptamer expressions for patients in EP6 that received mechanical ventilation (MV+) versus those that did not (MV-). Two-sided Mann–Whitney U (MWU) tests followed by Benjamini-Hochberg method for adjusting p-values were used to calculate false discovery rates. B) Distribution of age and BMI of MV+ and MV- patients in EP6. Pvalues are calculated using two-sided MWU tests. C) The status of sex for MV+ and MV- patients in EP6. P-value is calculated using a Fisher's exact test. D) The scatter plot shows the correlation between expression of IDUA aptamer and number of days that patients received mechanical ventilation (n = 50).

389 Tables

390

391 Table 1: Reactome pathways associated with EP6, based on expression of aptamers. KnowEnG 392 analytical platform was used. The p-values were calculated using a one-sided Fisher's exact test 393 and were corrected for multiple tests using Benjamini–Hochberg method. Only signaling 394 pathways with FDR < 5E-4 are shown in this table (see Table S1 for the full list).</p>

395

Pathway	FDR
Signaling by Interleukins	2.75E-12
Cytokine Signaling in Immune system	6.25E-10
Immune System	2.28E-06
Signaling by FGFR	4.75E-06
Constitutive Signaling by Aberrant PI3K in Cancer	2.94E-05
FGFR2 ligand binding and activation	5.77E-05
Extracellular matrix organization	1.85E-04
FGFR3 ligand binding and activation	1.85E-04
FGFR3c ligand binding and activation	1.85E-04
FGFRL1 modulation of FGFR1 signaling	1.85E-04
TNFs bind their physiological receptors	2.58E-04
PI3K/AKT Signaling in Cancer	3.28E-04
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	4.14E-04
Interleukin-4 and 13 signaling	4.91E-04

Table 2: Aptamers associated with mechanical ventilation in EP6.

398 In this table, p-values are obtained using a two-sided Mann–Whitney U test and is corrected for

399 multiple tests using Benjamini–Hochberg FDR. A value of +1 (-1) in the "sign" column shows that

400 the value of aptamer was higher (lower) in the samples of 55 patients that received mechanical

401 ventilation in EP6, compared to the rest of EP6 members. Only 14 targets with FDR < 1.2E-02 are

- 402 shown. The full list is provided in Table S4.
- 403

Target	Target Full Name	p-values	FDR	Direction
GGE2D	G antigen 2D	2.93E-08	1.46E-04	+1
ANGPTL3	Angiopoietin-related protein 3	2.76E-06	4.58E-03	+1
Luteinizing hormone	Luteinizing hormone	2.55E-06	4.58E-03	-1
CRBS	Beta-crystallin S	1.01E-05	8.37E-03	-1
NCAM-120	Neural cell adhesion molecule 1; 120 kDa isoform	8.78E-06	8.37E-03	-1
SIA10	Type 2 lactosamine alpha-2;3-sialyltransferase	7.36E-06	8.37E-03	-1
LRP1	Prolow-density lipoprotein receptor-related protein 1	2.77E-05	1.16E-02	-1
CLM2	CMRF35-like molecule 2	2.70E-05	1.16E-02	-1
THS7A	Thrombospondin type-1 domain-containing protein 7A	1.65E-05	1.16E-02	-1
LAP	Cytosol aminopeptidase	3.04E-05	1.16E-02	-1
CXCL16	C-X-C motif chemokine 16	2.64E-05	1.16E-02	+1
FSH	Follicle stimulating hormone	2.52E-05	1.16E-02	-1
VEGF sR2	Vascular endothelial growth factor receptor 2	3.27E-05	1.16E-02	-1
ASGR1	Asialoglycoprotein receptor 1	2.97E-05	1.16E-02	+1

SNV ID	Position	Gene Symbol	SNV ¹	MAF	HWE	OR ²	p-value
rs1394671	chr5:7348567	-	G > A	0.240	0.095	2.28	2.41E-06
rs12186698	chr5:168880668	SLIT3	T > C	0.087	0.247	2.93	3.72E-06
rs11625406	chr14:50049474	-	C > A	0.438	0.137	0.47	1.03E-05
rs11862889	chr16:83828886	-	T > C	0.104	0.446	2.62	1.07E-05
rs2995918	chr4:37905775	TBC1D1	C > T	0.494	0.776	0.49	1.20E-05
rs16897810	chr5:68415296	-	G > A	0.093	0.001	2.67	1.43E-05
rs2376263	chr17:35436659	SLFN13	G > A	0.261	0.073	2.01	2.48E-05
rs4790712	chr17:1614620	SLC43A2	G > A	0.441	0.003	1.97	2.50E-05
rs2294566	chr20:41472939	CHD6	C > A	0.239	0.265	2.04	2.78E-05
rs7164451	chr15:48921859	SHC4	G > A	0.386	0.053	1.89	3.01E-05
rs57664621	chr8:22808443	PEBP4	G > C	0.174	0.016	2.16	3.07E-05
rs28482919	chr3:14903094	FGD5	T > C	0.187	0.053	0.32	3.20E-05
rs6559283	chr9:89712560	-	T > C	0.375	<0.001	1.96	3.27E-05
rs657075	chr5:132094425	-	A > G	0.104	0.328	2.49	4.28E-05
rs56235109	chr15:62424001	TLN2	A > G	0.235	0.366	0.38	4.67E-05
rs7620057	chr3:179473377	GNB4	T > C	0.099	1.000	2.51	4.67E-05
rs10466868	chr12:131455375	-	T > G	0.108	0.401	2.51	5.94E-05
rs2236798	chr1:18735127	PAX7	A > G	0.054	0.114	2.90	6.11E-05
rs3774814	chr4:5464702	STK32B	C > G	0.205	<0.001	0.36	6.75E-05
rs4497815	chr19:22903215	-	G > A	0.216	0.205	2.07	7.52E-05
rs6765694	chr3:54601810	CACNA2D3	G > A	0.404	0.833	0.51	7.66E-05
rs2797773	chr6:37559045	-	C > T	0.422	0.000	0.53	8.06E-05
rs17014760	chr4:129419725	-	A > A	0.316	0.000	1.89	9.33E-05
rs10948260	chr6:45835559	-	G > A	0.366	0.189	1.81	9.52E-05
rs12035677	chr1:232391209	-	A > G	0.063	0.000	3.02	9.95E-05

405 **Table 3**: SNVs differentiating EP6 against all other endophenotype clusters.

Abbreviations used: SNV = Single nucleotide variation, HWE = Hardy Weinberg Equilibrium, MAF
 = Minor allele frequency, OR = Odd ratio.

408

¹ SNV are described following GWAS annotations: refence allele > alternative allele (e.g., G > A).

410 ² Logistic regression analyses using additive model adjusted for the 2 principal components.

412 Table 4: Association between gen	otypes and aptamer expression levels
--------------------------------------	--------------------------------------

SNV	Gene Symbol	Nearest gene	Aptamers normalized expression ¹			Multiple logistic regression analyses ³				
			HM _{ref}	HTZ	HM _{alt}	p-val ²	Aptamers OR	p-val	SNV OR	p-val
rs6765694	CACNA2D3	-	-0.09 (±0.89)	0.01 (±1.10)	0.24 * (±0.99)	0.011	0.61 (0.46-0.79)	2.5E-4	0.52 (0.37-0.74)	2.4E-4
rs10948260	-	CLIC5	0.02 (±0.92)	0.02 (±1.09)	-0.02 (±0.97)	0.796	0.68 (0.55-0.83)	1.7E-4	1.83 (1.35-2.48)	8.8E-5
rs657075	-	IL3	-0.01 (±1.01)	0.05 (±0.99)	0.32 (±0.46)	0.328	1.37 (1.14-11.64)	8.2E-4	2.49 (1.60-3.88)	5.2E-5
rs7164451	SHC4	-	-0.07 (±0.90)	0.01 (±1.05)	0.23 * (±1.16)	0.017	11.98 (7.61-18.87)	8.4E- 27	2.00 (1.30-3.09)	1.8E-3
rs12186698	SLIT3	-	0.00 (±1.02)	0.07 (±1.06)	0.15 (±0.89)	0.509	0.82 (0.64-1.06)	0.135	2.99 (1.89-4.73)	2.7E-6
rs56235109	TLN2	-	-0.03 (±0.98)	0.06 (±1.03)	0.04 (±1.27)	0.353	0.58 (0.45-0.75)	2.7E-5	0.38 (0.23-0.60)	4.7E-5

413 Abbreviations used: SNV = Single nucleotide variation, HM_{ref} = Homozygotes for the reference

allele, HM_{alt} = Homozygotes for the alternative allele, HTZ = Heterozygotes, OR = Odd ratio.

415

¹ Aptamers' normalized levels of expression are reported as mean (± standard deviation).
 Normalization steps for aptamer expressions are described in Methods.

² p-value, standard ANOVA analyses followed by Tukey *post hoc* analyses. Asterisks (*) identify
 difference between HM_{ref} and HM_{alt} genotypes.

³ Multiple logistic regression analyses models include aptamers expression values, SNV
 genotypes (additive model) and the two principal components. OR are reported with 95%
 confidence intervals in parentheses.

424 425 **References**

- Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for
 Coronavirus Disease 2019 (COVID-19): A Review. *JAMA* 2020; 323: 1824-1836.
- Lim ZJ, Subramaniam A, Ponnapa Reddy M, Blecher G, Kadam U, Afroz A, et al. Case
 Fatality Rates for Patients with COVID-19 Requiring Invasive Mechanical Ventilation. A
 Meta-analysis. *Am J Respir Crit Care Med* 2021; 203: 54-66.
- 431 3. Berrettini WH. Genetic bases for endophenotypes in psychiatric disorders. *Dialogues Clin*432 *Neurosci* 2005; 7: 95-101.
- 4. Froidure A, Mouthuy J, Durham SR, Chanez P, Sibille Y, Pilette C. Asthma phenotypes and
 434 IgE responses. *Eur Respir J* 2016; 47: 304-19.
- 435 5. Barnes PJ. Inflammatory endotypes in COPD. *Allergy* 2019; 74: 1249-1256.
- 436 6. Koennecke M, Klimek L, Mullol J, Gevaert P, Wollenberg B. Subtyping of polyposis nasi:
 437 phenotypes, endotypes and comorbidities. *Allergo J Int* 2018; 27: 56-65.
- 438 7. Baghela A, An A, Zhang P, Acton E, Gauthier J, Brunet-Ratnasingham E, et al. Predicting
 439 severity in COVID-19 disease using sepsis blood gene expression signatures. *Sci Rep* 2023;
 440 13: 1247.
- 441 8. LaSalle TJ, Gonye ALK, Freeman SS, Kaplonek P, Gushterova I, Kays KR, et al. Longitudinal
 442 characterization of circulating neutrophils uncovers phenotypes associated with severity
 443 in hospitalized COVID-19 patients. *Cell Rep Med* 2022; 3: 100779.
- Ma W, Soulé A, Tremblay K, Rousseau S, Emad A. A circulating proteome-informed
 prognostic model of COVID-19 disease activity that relies on routinely available clinical
 laboratories. *medRxiv* 2022: 2022.11.02.22281834.
- Welin A, Amirbeagi F, Christenson K, Björkman L, Björnsdottir H, Forsman H, et al. The
 Human Neutrophil Subsets Defined by the Presence or Absence of OLFM4 Both
 Transmigrate into Tissue In Vivo and Give Rise to Distinct NETs In Vitro. *PLOS ONE* 2013;
 8: e69575.
- 451 11. Blatti III C, Emad A, Berry MJ, Gatzke L, Epstein M, Lanier D, et al. Knowledge-guided
 452 analysis of "omics" data using the KnowEnG cloud platform. *PLoS biology* 2020; 18:
 453 e3000583.
- 454 12. Gillespie M, Jassal B, Stephan R, Milacic M, Rothfels K, Senff-Ribeiro A, et al. The reactome
 455 pathway knowledgebase 2022. *Nucleic Acids Research* 2021; 50: D687-D692.

- 456 13. Blachier F, Andriamihaja M, Blais A. Sulfur-Containing Amino Acids and Lipid Metabolism.
 457 The Journal of Nutrition 2020; 150: 2524S-2531S.
- 45814.Ye C, Sutter BM, Wang Y, Kuang Z, Tu BP. A metabolic function for phospholipid and459histone methylation. *Molecular cell* 2017; 66: 180-193. e8.
- Tavoosi N, Davis-Harrison RL, Pogorelov TV, Ohkubo YZ, Arcario MJ, Clay MC, et al.
 Molecular Determinants of Phospholipid Synergy in Blood Clotting. *Journal of Biological Chemistry* 2011; 286: 23247-23253.
- Parman T, Bunin DI, Ng HH, McDunn JE, Wulff JE, Wang A, et al. Toxicogenomics and
 metabolomics of pentamethylchromanol (PMCol)-induced hepatotoxicity. *Toxicological Sciences* 2011; 124: 487-501.
- 466 17. Grohmann U, Volpi C, Fallarino F, Bozza S, Bianchi R, Vacca C, et al. Reverse signaling
 467 through GITR ligand enables dexamethasone to activate IDO in allergy. *Nature Medicine*468 2007; 13: 579-586.
- Marfia G, Navone S, Guarnaccia L, Campanella R, Mondoni M, Locatelli M, et al. Decreased
 serum level of sphingosine-1-phosphate: a novel predictor of clinical severity in COVID-*EMBO molecular medicine* 2021; 13: e13424.
- 472 19. Lone MA, Hülsmeier AJ, Saied EM, Karsai G, Arenz C, von Eckardstein A, et al. Subunit
 473 composition of the mammalian serine-palmitoyltransferase defines the spectrum of
 474 straight and methyl-branched long-chain bases. *Proceedings of the National Academy of*475 *Sciences* 2020; 117: 15591-15598.
- 476 20. Han G, Gupta SD, Gable K, Niranjanakumari S, Moitra P, Eichler F, et al. Identification of
 477 small subunits of mammalian serine palmitoyltransferase that confer distinct acyl-CoA
 478 substrate specificities. *Proceedings of the National Academy of Sciences* 2009; 106: 8186479 8191.
- 480 21. Chen PY, Gao WY, Liou JW, Lin CY, Wu MJ, Yen JH. Angiopoietin-Like Protein 3 (ANGPTL3)
 481 Modulates Lipoprotein Metabolism and Dyslipidemia. *Int J Mol Sci* 2021; 22.
- 482 22. Lachkar F, Ferré P, Foufelle F, Papaioannou A. Dihydroceramides: their emerging
 483 physiological roles and functions in cancer and metabolic diseases. *American Journal of*484 *Physiology-Endocrinology and Metabolism* 2021; 320: E122-E130.
- 485 23. Koishi R, Ando Y, Ono M, Shimamura M, Yasumo H, Fujiwara T, et al. Angptl3 regulates
 486 lipid metabolism in mice. *Nature Genetics* 2002; 30: 151-157.

Pisciotta L, Favari E, Magnolo L, Simonelli S, Adorni MP, Sallo R, et al. Characterization of
Three Kindreds With Familial Combined Hypolipidemia Caused by Loss-of-Function
Mutations of ANGPTL3. *Circulation: Cardiovascular Genetics* 2012; 5: 42-50.

Lekka ME, Liokatis S, Nathanail C, Galani V, Nakos G. The Impact of Intravenous Fat
Emulsion Administration in Acute Lung Injury. *American Journal of Respiratory and Critical Care Medicine* 2004; 169: 638-644.

- 493 26. Ahmad Z, Banerjee P, Hamon S, Chan K-C, Bouzelmat A, Sasiela WJ, et al. Inhibition of
 494 Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in
 495 Hypertriglyceridemia. *Circulation* 2019; 140: 470-486.
- 49627.Bie H, Yin J, He X, Kermode AR, Goddard-Borger ED, Withers SG, et al. Insights into497mucopolysaccharidosis I from the structure and action of α -L-iduronidase. Nature498Chemical Biology 2013; 9: 739-745.
- Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk
 of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective
 cohort study. *Intensive Care Medicine* 2020; 46: 1089-1098.
- 50229.Asakura H, Ogawa H. COVID-19-associated coagulopathy and disseminated intravascular503coagulation. International Journal of Hematology 2021; 113: 45-57.
- 504 30. Fahmy OH, Daas FM, Salunkhe V, Petrey JL, Cosar EF, Ramirez J, et al. Is Microthrombosis
 505 the Main Pathology in Coronavirus Disease 2019 Severity?-A Systematic Review of the
 506 Postmortem Pathologic Findings. *Crit Care Explor* 2021; 3: e0427.
- Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J, Crawford JM, et al.
 Targeting potential drivers of COVID-19: Neutrophil extracellular traps. *Journal of Experimental Medicine* 2020; 217.
- 32. Bonaventura A, Vecchié A, Dagna L, Martinod K, Dixon DL, Van Tassell BW, et al.
 Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID19. Nature Reviews Immunology 2021; 21: 319-329.
- 513 33. Ding J, Hostallero DE, El Khili MR, Fonseca GJ, Milette S, Noorah N, et al. A network-514 informed analysis of SARS-CoV-2 and hemophagocytic lymphohistiocytosis genes' 515 interactions points to Neutrophil extracellular traps as mediators of thrombosis in COVID-516 19. *PLoS Computational Biology* 2021; 17: e1008810.
- 51734.Blasco A, Coronado M-J, Hernández-Terciado F, Martín P, Royuela A, Ramil E, et al.518Assessment of neutrophil extracellular traps in coronary thrombus of a case series of519patients with COVID-19 and myocardial infarction. JAMA cardiology 2021; 6: 469-474.
- 520 35. Desilles JP, Solo Nomenjanahary M, Consoli A, Ollivier V, Faille D, Bourrienne MC, et al.
 521 Impact of COVID-19 on thrombus composition and response to thrombolysis: Insights
 522 from a monocentric cohort population of COVID-19 patients with acute ischemic stroke.
 523 Journal of Thrombosis and Haemostasis 2022; 20: 919-928.

- 52436.Englert H, Rangaswamy C, Deppermann C, Sperhake J-P, Krisp C, Schreier D, et al.525Defective NET clearance contributes to sustained FXII activation in COVID-19-associated526pulmonary thrombo-inflammation. *EBioMedicine* 2021; 67: 103382.
- 527 37. Leppkes M, Knopf J, Naschberger E, Lindemann A, Singh J, Herrmann I, et al. Vascular 528 occlusion by neutrophil extracellular traps in COVID-19. *EBioMedicine* 2020; 58: 102925.
- Middleton EA, He X-Y, Denorme F, Campbell RA, Ng D, Salvatore SP, et al. Neutrophil
 extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory
 distress syndrome. *Blood* 2020; 136: 1169-1179.
- 53239.Obermayer A, Jakob L-M, Haslbauer JD, Matter MS, Tzankov A, Stoiber W. Neutrophil533extracellular traps in fatal COVID-19-associated lung injury. *Disease markers* 2021; 2021.
- 40. Ouwendijk WJ, Raadsen MP, Van Kampen JJ, Verdijk RM, Von Der Thusen JH, Guo L, et al.
 High levels of neutrophil extracellular traps persist in the lower respiratory tract of
 critically ill patients with coronavirus disease 2019. *The Journal of infectious diseases*2021; 223: 1512-1521.
- Petito E, Falcinelli E, Paliani U, Cesari E, Vaudo G, Sebastiano M, et al. Association of
 neutrophil activation, more than platelet activation, with thrombotic complications in
 coronavirus disease 2019. *The Journal of infectious diseases* 2021; 223: 933-944.
- 541 42. Skendros P, Mitsios A, Chrysanthopoulou A, Mastellos DC, Metallidis S, Rafailidis P, et al.
 542 Complement and tissue factor–enriched neutrophil extracellular traps are key drivers in
 543 COVID-19 immunothrombosis. *The Journal of clinical investigation* 2020; 130: 6151-6157.
- 43. Massberg S, Grahl L, von Bruehl M-L, Manukyan D, Pfeiler S, Goosmann C, et al. Reciprocal
 545 coupling of coagulation and innate immunity via neutrophil serine proteases. *Nature*546 *Medicine* 2010; 16: 887-896.
- 547 44. Papayannopoulos V, Metzler KD, Hakkim A, Zychlinsky A. Neutrophil elastase and
 548 myeloperoxidase regulate the formation of neutrophil extracellular traps. *Journal of Cell*549 *Biology* 2010; 191: 677-691.
- 45. Alder MN, Opoka AM, Lahni P, Hildeman DA, Wong HR. Olfactomedin-4 Is a Candidate
 Marker for a Pathogenic Neutrophil Subset in Septic Shock. *Critical Care Medicine* 2017;
 45: e426-e432.
- 55346.Stafford JH, Thorpe PE. Increased exposure of phosphatidylethanolamine on the surface554of tumor vascular endothelium. *Neoplasia* 2011; 13: 299-IN2.
- 55547.Ran S, Downes A, Thorpe PE. Increased exposure of anionic phospholipids on the surface556of tumor blood vessels. *Cancer research* 2002; 62: 6132-6140.

48. Port JR, Adney DR, Schwarz B, Schulz JE, Sturdevant DE, Smith BJ, et al. High-fat high-sugar
diet-induced changes in the lipid metabolism are associated with mildly increased COVID19 severity and delayed recovery in the Syrian hamster. *Viruses* 2021; 13: 2506.

- MacDonald J, Sprecher H. Distribution of arachidonic acid in choline-and ethanolaminecontaining phosphoglycerides in subfractionated human neutrophils. *Journal of Biological Chemistry* 1989; 264: 17718-17726.
- 563 50. Papageorgiou C, Jourdi G, Adjambri E, Walborn A, Patel P, Fareed J, et al. Disseminated 564 intravascular coagulation: an update on pathogenesis, diagnosis, and therapeutic 565 strategies. *Clinical and Applied Thrombosis/Hemostasis* 2018; 24: 8S-28S.
- 566 51. Lacal PM, Petrillo MG, Ruffini F, Muzi A, Bianchini R, Ronchetti S, et al. Glucocorticoidinduced tumor necrosis factor receptor family-related ligand triggering upregulates
 vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 and promotes
 leukocyte adhesion. J Pharmacol Exp Ther 2013; 347: 164-72.
- 570 52. Pandit R, Singh I, Ansari A, Raval J, Patel Z, Dixit R, et al. First report on genome wide
 571 association study in western Indian population reveals host genetic factors for COVID-19
 572 severity and outcome. *Genomics* 2022; 114: 110399.
- 573 53. Goligher EC, Bradbury CA, McVerry BJ, Lawler PR, Berger JS, Gong MN, et al. Therapeutic
 574 Anticoagulation with Heparin in Critically III Patients with Covid-19. *N Engl J Med* 2021;
 575 385: 777-789.
- 576 54. Lawler PR, Goligher EC, Berger JS, Neal MD, McVerry BJ, Nicolau JC, et al. Therapeutic
 577 Anticoagulation with Heparin in Noncritically III Patients with Covid-19. *N Engl J Med*578 2021; 385: 790-802.
- 579 55. Smadja DM, Philippe A, Bory O, Gendron N, Beauvais A, Gruest M, et al. Placental growth
 580 factor level in plasma predicts COVID-19 severity and in-hospital mortality. *Journal of*581 *Thrombosis and Haemostasis* 2021; 19: 1823-1830.
- 582 56. Bussolari C, Palumbo D, Fominsky E, Nardelli P, De Lorenzo R, Vitali G, et al. Case Report:
 583 Nintedaninb May Accelerate Lung Recovery in Critical Coronavirus Disease 2019. *Frontiers*584 *in Medicine* 2021; 8: 766486.
- 58557.Liu W, Peng Y, Tobin DJ. A new 12-gene diagnostic biomarker signature of melanoma586revealed by integrated microarray analysis. *PeerJ* 2013; 1: e49.
- 587 58. Luo S, Feofanova EV, Tin A, Tung S, Rhee EP, Coresh J, et al. Genome-wide association 588 study of serum metabolites in the African American Study of Kidney Disease and 589 Hypertension. *Kidney International* 2021; 100: 430-439.

- 590 59. Agarwal B, Gatt A, Riddell A, Wright G, Chowdary P, Jalan R, et al. Hemostasis in patients
 591 with acute kidney injury secondary to acute liver failure. *Kidney International* 2013; 84:
 592 158-163.
- 593 60. Williams R, Schalm SW, O'Grady JG. Acute liver failure: redefining the syndromes. *The* 594 *Lancet* 1993; 342: 273-275.
- 595 61. Durinck S, Spellman PT, Birney E, Huber W. Mapping identifiers for the integration of
 596 genomic datasets with the R/Bioconductor package biomaRt. *Nature Protocols* 2009; 4:
 597 1184-1191.
- 59862.R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria:599R Foundation for Statistical Computing; 2022. Available from: https://www.R-600project.org/.
- 63. Marees AT, de Kluiver H, Stringer S, Vorspan F, Curis E, Marie-Claire C, et al. A tutorial on
 conducting genome-wide association studies: Quality control and statistical analysis. *Int J Methods Psychiatr Res* 2018; 27: e1608.
- 60464.Ochoa A. genio: Genetics Input/Output Functions. R package version 1.1.1; 2022. Available605from: https://CRAN.R-project.org/package=genio.
- 606 65. Warnes G, Gorjanc G, Leisch F, Man M. *genetics: Population Genetics*. R package version
 607 1.3.8.1.3; 2021. Available from: <u>https://CRAN.R-project.org/package=genetics</u>.
- 608 66. Zheng X, Levine D, Shen J, Gogarten SM, Laurie C, Weir BS. A high-performance computing
 609 toolset for relatedness and principal component analysis of SNP data. *Bioinformatics*610 2012; 28: 3326-3328.
- 611 67. Perdry H, Dandine-Roulland C. *gaston: Genetic Data Handling (QC, GRM, LD, PCA)* &
 612 *Linear Mixed Models*. R package version 1.5.7; 2020. Available from: <u>https://CRAN.R-</u>
 613 project.org/package=gaston.